Pharma Turkey Dergisi Eylül – Ekim 2017 Sayısı

A new option in cancer treatment: living drugs!
Turkey’s First Genetically Modified Cell Therapy Data announced at the
4th Hematologic Oncology Congress.
Turkish scientists have succeeded in
producing the genetically modified
cell therapy called 'living drug', the
newest method in cancer treatment,
in the laboratory environment in Turkey.
Genetically modified cell therapy
laboratory data in various diseases in
which Turkey's cancer, first time 16
to 17 September 2017 between the
TRNC held on 4.Hematolojik Oncology
Congress explaining, treating January
2018 as leukemia, lymphoma and
multiple myeloma is aimed at testing
patients with blood. If successful,
candidate patients will have the option
of choosing this therapy, which has
been in place for over a year in the
US and cost as high as about half a
trillion; Turkish scientists will be able
to reach more affordable prices with
their production.
Lymphoma, multiple myeloma, blood
cancers such as leukemia cells induced
that recent developments in hematological
cancers, Hematologic Oncology
Society (HOD) were addressed
in the Hematologic Oncology Congress
held by the fourth this year. The
congress held 16 to 17 September
in Elexus Convention Center in Trnc
-Turkish Republic of Northern Cyprus
with 190 hematalog total of 270 people
attended. At the press conference
held within the scope of the Congress,
Professor Dr. Seckin Cagırgan
President of Hematological Oncology
Association and members of the Board
of Directors, Prof. Dr. Sevgi Kalayoglu
Besisik, Assoc. Dr. Anil Tombak,
Assoc. Dr. Emre Tekgunduz and the
recent "Blood and Stem Cells Synthetic
Leather Production" with one
of the world's prestigious medicine
award-winning Turkish scientist
Prof. Dr. Ercument Ovali shared their
information.
Abroad to Significantly Reduce
the Need for Bone Marrow Bank
With TÜRKÖK...
The first word of the Association
of Hematologic Oncology Professor.
Dr. Seckin Cagırgan stated that
every year in the scope of the Congress,
one disease is taken ahead. This
year, the significance of developments
in the field of acute leukemia Prof.
Dr. Seckin Cagirgan shared attention,
said, "Acute myeloid leukemia
treatment had not experienced a
significant improvement almost 40
years. In patients with chemotherapy
response was obtained from someone
else transplant outcomes of allogeneic
transplants from non-related
persons was improved when necessary.
But the first step, that is, before
the transplantation of cancer cell
purification treatment was not a significant
development.”
Declaring that the current situation
in the context of targeted therapy in
appropriate patients, which would
start the implementation of the
new drug the development of the
disease has been reported multiple
treatment of other serious, Prof.
Cagirgan, said: "Multiple There was
a movement in the field of myeloma
treatment last 10 years. Multiple
new drug life of myeloma patients
longer. Relatives donors, and without
necessarily Turkey to patients in
need of transplants bone marrow donor
detection rate with TÜRKÖK
joined between banks, it was increased
in significant numbers, thus the
foreign bone marrow to reduce our
dependence on banks. Even unrelated
donor not exist, our patients are
not fully compatible relatives, parents
of even 50 percent of the brother or
sister of children consistent though
that - we can meet the needs of our
patients by making true of transport
for almost every patient to find such
a donor. We can get rid of our patients
and we apply it successfully in
our country.
Pharma
September- October ‘17 13